With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
Site Search
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
Funding will support clinical trials for therapy that could help improve digestion in people with CF
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
Two-thirds of people with cystic fibrosis in the U.S. experience debt, food insecurity, or housing issues.
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
206 care center directors sign a letter citing clinical consequences if decision moves forward.
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.